Xcout Intel
NanoSyrinx
NanoSyrinx Ltd. is a biotechnology company incorporated in England and Wales with headquarters in Warwick, focused on advancing targeted drug delivery platforms.
Subscribe to see NanoSyrinx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NanoSyrinx at a glance
NanoSyrinx is a biotechnology company headquartered in United Kingdom. It has raised at least $21M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $13.3M in September 2024. Xcout tracks 11 named people at NanoSyrinx, including Tom Farrell (CEO).
NanoSyrinx leadership
- Tom FarrellCEO
- Dr. James LapworthChief Business Officer
- Dr. Marie McAvoyChief Scientific Officer
- Dr Edwin MosesChairman of the Board
- Dr. Joseph HealeyFounder
- Prof. Nicholas WaterfieldScientific Advisor and Co-founder
5 more named people on record for NanoSyrinx, with roles, board committees and tenure — see the full roster →
NanoSyrinx funding rounds
At least $21M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $13.3M | 7 named | |
| Seed | $8.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
NanoSyrinx competitors
A few of NanoSyrinx's closest competitors — see the full list of competitors and alternatives →
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
NanoGhost is a biotechnology company that develops a targeted drug delivery platform using nanovesicles derived from the cell membranes of mesenchymal stem cells. The company serves the medical and pharmaceutical sectors by creating technologies designed to selectively target cancer and sites of inflammation for improved therapeutic delivery.
Phoreus Biotechnology, Inc. is a privately held biotechnology company founded in 2018 and headquartered in Olathe, Kansas. The company specializes in the development of proprietary nanocarriers for targeted drug delivery and enhanced treatments.
NERx Biosciences, Inc. is a small business enterprise headquartered in Indianapolis, Indiana, dedicated to the discovery and development of targeted therapeutics for cancer.
HelixNano is a biotechnology research company headquartered in Boston, Massachusetts, focused on developing advanced mRNA platform technologies for therapeutics.
Mironid Limited is a privately held drug discovery company founded in 2015 and headquartered in Glasgow, Scotland. The patient-focused company develops innovative therapeutics to improve the treatment of various medical conditions.
Get NanoSyrinx's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NanoSyrinx in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access